Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib

Autor:	Daniela Diverio, Concetta Micalizzi, Francesca Tucci, Caterina Consarino, Michelina Santopietro, Rosamaria Mura, Nicola Santoro, Anna Leszl, Fiorina Giona, Robin Foà, Franco Locatelli, Grazia Iaria, Roberta Burnelli, Saverio Ladogana, Mauro Nanni, Giuseppe Saglio, Carlo Cosmi, Giuseppe Menna, Maria Luisa Moleti, Maria Caterina Putti, Andrea Biondi
Přispěvatelé:	Giona, F, Saglio, G, Santopietro, M, Menna, G, Putti, M, Micalizzi, C, Iaria, G, Santoro, N, Ladogana, S, Mura, R, Burnelli, R, Consarino, C, Cosmi, C, Moleti, M, Leszl, A, Tucci, F, Nanni, M, Diverio, D, Biondi, A, Locatelli, F, Foà, R
Jazyk:	angličtina
Rok vydání:	2018
Předmět:	Male Oncology medicine.medical_specialty Adolescent Chronic myeloid leukaemia 03 medical and health sciences tyrosine kinase inhibitor 0302 clinical medicine childhood leukaemia Internal medicine tyrosine kinase inhibitors medicine Humans Chronic CML early response outcome Child Child Preschool Female Imatinib Mesylate Leukemia Myelogenous Chronic BCR-ABL Positive Hematology Preschool Leukemia business.industry Imatinib Childhood leukaemia Imatinib mesylate Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA 030220 oncology & carcinogenesis BCR-ABL Positive business Myelogenous 030215 immunology medicine.drug
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b0f725d71b3768ab7cd1dbe358fd2e7 https://hdl.handle.net/10807/230070 Zobrazit plný text záznamu